Patents by Inventor Meiyu Geng

Meiyu Geng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10766889
    Abstract: The invention describes an aryl-2,2?-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2?-tandem bisthiazole compound with the structure as shown in general formula I and the preparation method thereof and use thereof as a histone deacetylase inhibitor in the preparation of antitumor drugs.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: September 8, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Fajun Nan, Jia Li, Jian Ding, Meiyu Geng, Yangming Zhang, Yi Chen, Yubo Zhou, Chaojun Gong, Mingbo Su, Anhui Gao
  • Publication number: 20200247781
    Abstract: The invention relates to a compound of formula (I): wherein variables are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g. ERK1 and/or ERK2 kinase. The invention also relates to the use of the compound and a method for preparing the compound, and a pharmaceutical composition containing the compound.
    Type: Application
    Filed: September 29, 2018
    Publication date: August 6, 2020
    Inventors: Lei LI, Meiyu GENG, Ying HUANG, Jian DING, Qiong ZHANG, Min HUANG, Shuai TANG, Ning SHEN, Yi CHEN
  • Patent number: 10710996
    Abstract: The present invention discloses a pyrido-azacyclic compound represented by formula I, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, a preparation process thereof and a composition comprising the compound, and a use thereof as a multi-target protein kinase inhibitor in the preparation of a medicament for the treatment of diseases that are associated with protein kinase, especially c-Met, such as cancer and the like. The compound represented by formula I has potent inhibitory activity on tumor cells with overexpression of c-Met kinase, can effectively target c-Met-mediated signaling pathway, and can be used in the treatment of diseases such as cancer and the like that is caused by the overexpression of c-Met kinase.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: July 14, 2020
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Yaqiu Long, Meiyu Geng, Zhongliang Xu, Jing Ai
  • Patent number: 10682352
    Abstract: Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: June 16, 2020
    Assignees: SHANGHAI HAIHE PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Lei Jiang, Meiyu Geng, Qiangang Zheng, Min Huang, Huixin Wan, Shuai Tang, Xianlei Fu, Xiaojing Lan, Jianhua Cao, Feifei Liu, Jian Ding
  • Patent number: 10683278
    Abstract: Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: June 16, 2020
    Assignees: SHANGHAI HAIHE PHARMACEUTICAL CO., LTD., JINAN UNIVERSITY, SHANGHAI INTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Ke Ding, Meiyu Geng, Li Tan, Jian Ding, Zhang Zhang, Jing Ai, Xiaomei Ren, Donglin Gao, Zhengchao Tu, Xiaoyun Lu, Dongmei Zhang
  • Publication number: 20200172510
    Abstract: Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 4, 2020
    Inventors: Ao ZHANG, Meiyu GENG, Li XING, Jing AI, Zilan SONG, Xia PENG, Wangting GU, Jian DING
  • Publication number: 20200055838
    Abstract: An o-aminoheteroaryl alkynyl-containing compound has a structure represented by formula (I), and the compound of formula (I) has advantages of a high FGFR and RET double target inhibitory activity and a relatively low KDR activity, and the compound of formula (I) exhibits a strong inhibitory activity in a human lung cancer cell line NCI-H1581 and a gastric cancer cell line SNU16 as well as an RET-dependent sensitive cell line BaF3-CCDC6-Ret and a mutant thereof. Pharmacokinetic data shows that the o-aminoheteroaryl alkynyl-containing compound has druggability, and exhibits significant relevant inhibition of the growth of related tumors in a long-term animal model of drug efficacy and results in favorable animal condition at effective doses.
    Type: Application
    Filed: February 12, 2018
    Publication date: February 20, 2020
    Inventors: Youhong HU, Meiyu GENG, Wenming REN, Jian DING, Xiaocong GUAN, Jing AI, Lang WANG, Xia PENG, Yang LIU, Yang DAI, Limin ZENG
  • Publication number: 20200055888
    Abstract: The invention relates to a new method of preparing oligomannuronic diacids, important bioactives. The method utilizes oligomannuronic acids as starting materials and the target substances are obtained by acid degradation and active hypobromous acid oxidation steps. The method of preparing oligomannuronic diacids according to the invention employs moderate reaction conditions, has few side reactions, does not need further purification, achieves a yield of more than 90%, or even more than 95%, and is suitable for production with an on-line continuous reactor device, with reaction processes easy to implement automatic control.
    Type: Application
    Filed: August 15, 2016
    Publication date: February 20, 2020
    Inventors: Zhongping Xiao, Zhenqing Zhang, Meiyu Geng, Jian Ding
  • Patent number: 10562900
    Abstract: The present invention provides an indazole compound as a FGFR kinase inhibitor, preparation and use thereof. Specifically, the present invention provides a compound represented by formula (I), wherein the definitions of each group are described in the specification. The compound of the present invention has good FGFR kinase-inhibiting activity, and can be used in preparing a series of medicines for treating FGFR kinase activity related diseases.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: February 18, 2020
    Assignees: Shanghai Haihe Pharmaceutical Co., Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Meiyu Geng, Lei Liu, Lei Jiang, Min Huang, Chuantao Zha, Jing Ai, Lei Wang, Jianhua Cao, Jian Ding
  • Publication number: 20190367520
    Abstract: A new compound having an FGFR inhibitory activity and preparation and application thereof are provided. In particular, the compound according to the invention has a structure as shown in formula I, in which each group and substituent are as defined in the description. Also, a preparation method for the compound and a use thereof in preparation of a drug for treating and/or preventing a tumor-related disease and/or an FGFR-related disease are provided.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 5, 2019
    Inventors: Wenhu DUAN, Meiyu GENG, Yuming WANG, Jing AI, Jun FAN, Yang DAI, Jian DING
  • Publication number: 20190345184
    Abstract: The present invention relates to a method for degrading a polysaccharide in the field of food, medicine or chemical industry. In particular, a molecular chain of the polysaccharide is broken by ozone into polysaccharides with smaller molecular weights, oligoses and/or oligosaccharides. The polysaccharides include linear or branched glycans extracted from plants, traditional Chinese medicinal materials, animals, fungi, or microorganisms and sulfated polysaccharides or esterified polysaccharides formed by sulfation or esterification thereof. As an oxidizing agent in the reaction, the ozone can be used alone or can be used under the catalysis of a base, a metal ion, hydrogen peroxide, UV light, or activated carbon to accelerate the reaction.
    Type: Application
    Filed: December 27, 2017
    Publication date: November 14, 2019
    Inventors: Zhongping Xiao, Zhenqing Zhang, Meiyu Geng, Jian Ding
  • Publication number: 20190292183
    Abstract: The present disclosure relates to a Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method thereof and use thereof. The compounds of the present invention have good inhibitory activities against BTK at the molecular and cellular levels. Importantly, the compounds of the present invention have low activity against Ramos cells of normal human B lymphoma cells, and have high activity against BTK-sensitive human diffuse large B lymphoma TMD8 cells, indicating that these type of compounds with novel structural are highly selective, off-target phenomenon and corresponding side effects are low. Thus it is a selective inhibitor of BTK with development potential.
    Type: Application
    Filed: November 24, 2017
    Publication date: September 26, 2019
    Inventors: Ao Zhang, Jian Ding, Hua Xie, Zilan Song, Yu Xue, Linjiang Tong, Meiyu Geng
  • Publication number: 20190255092
    Abstract: The invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of ?-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedure that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2˜6 and the temperature of 100˜120° C., and adjusted pH to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 22, 2019
    Inventors: Meiyu Geng, Huashi Guan, Xianliang Xin, Zhao Yang, Guangqiang Sun
  • Publication number: 20190211010
    Abstract: The present invention provides a pyrido five-element aromatic ring compound, and a preparation method therefor and a use thereof. The compound provided in the present invention has an inhibitory effect on wild-type and/or mutant EZH2, and is well positioned to become a novel anti-tumor drug or a drug for the treatment of autoimmune diseases.
    Type: Application
    Filed: September 6, 2017
    Publication date: July 11, 2019
    Inventors: Xuxing CHEN, Meiyu GENG, Lei JIANG, Yi CHEN, Jianhua CAO, Qingyun JIANG, Qianqian SHEN, Jian DING, Yucai YAO, Zhao ZHAO, Yuanfang XIONG
  • Publication number: 20190211005
    Abstract: The invention describes an aryl-2,2?-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2?-tandem bisthiazole compound with the structure as shown in general formula I and the preparation method thereof and use thereof as a histone deacetylase inhibitor in the preparation of antitumor drugs.
    Type: Application
    Filed: August 24, 2017
    Publication date: July 11, 2019
    Inventors: Fajun NAN, Jia LI, Jian DING, Meiyu GENG, Yangming ZHANG, Yi CHEN, Yubo ZHOU, Chaojun GONG, Mingbo SU, Anhui GAO
  • Patent number: 10328060
    Abstract: Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
    Type: Grant
    Filed: November 1, 2015
    Date of Patent: June 25, 2019
    Assignees: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES, CHONGQING FOCHON PHARMACEUTICAL CO., LTD.
    Inventors: Xingdong Zhao, Jian Ding, Linghua Meng, Meiyu Geng, Tongshuang Li, Zuwen Zhou, Ling Chen, Qihong Liu, Xianlong Wang, Lijun Yang, Yue Rong, Rui Tan, Chuiliang Yu, Lihua Jiang, Yanxin Liu, Li Linghu, Jing Sun, Weibo Wang
  • Publication number: 20190135818
    Abstract: The present invention provides a compound comprising a 5-membered heterocycle fused with a pyridazinone, wherein the compound is used as an FGFR kinase inhibitor, and a manufacturing method and application thereof. The invention specifically provides a compound as represented by formula (I). Various radicals are as defined in the specification. The compound provided by the invention effectively inhibits an activity of an FGFR kinase, and can be used to manufacture a pharmaceutical product for treating a disease related to the activity of the FGFR kinase.
    Type: Application
    Filed: May 24, 2017
    Publication date: May 9, 2019
    Inventors: Hualiang JIANG, Hong LIU, Meiyu GENG, Mingyue ZHENG, Jing AI, Yulan WANG, Xiaowei WU, Shuangjie LI, Xia PENG, Chunpu LI, Kaixian CHEN, Bao WANG
  • Publication number: 20190111056
    Abstract: Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof.
    Type: Application
    Filed: March 21, 2017
    Publication date: April 18, 2019
    Inventors: Lei JIANG, Meiyu GENG, Qiangang ZHENG, Min HUANG, Huixin WAN, Shuai TANG, Xianlei FU, Xiaojing LAN, Jianhua CAO, Feifei LIU, Jian DING
  • Patent number: 10213456
    Abstract: The invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of ?-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedure that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2˜6 and the temperature of 100˜120° C., and adjusted pH to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: February 26, 2019
    Assignee: Ocean University Of China
    Inventors: Meiyu Geng, Huashi Guan, Xianliang Xin, Zhao Yang, Guangqiang Sun
  • Publication number: 20180265496
    Abstract: Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.
    Type: Application
    Filed: August 18, 2016
    Publication date: September 20, 2018
    Applicants: JINAN UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA,CHINESE ACADEMY OF SCIENCES
    Inventors: Ke DING, Meiyu GENG, Li TAN, Jian DING, Zhang ZHANG, Jing AI, Xiaomei REN, Donglin GAO, Zhengchao TU, Xiaoyun LU, Dongmei ZHANG